Skip to main content
Clinical Trials/NCT04479787
NCT04479787
Completed
Not Applicable

Dorsal Spinal Cord Stimulation vs Medical Management for the Treatment of Low Back Pain (DISTINCT)

Abbott Medical Devices30 sites in 1 country270 target enrollmentJuly 31, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Low-Back Pain
Sponsor
Abbott Medical Devices
Enrollment
270
Locations
30
Primary Endpoint
The Difference in Responders Between Both Groups
Status
Completed
Last Updated
last year

Overview

Brief Summary

The objective of this study is to evaluate the efficacy of BurstDR dorsal column stimulation, compared with conventional medical management, in improving pain and back-related physical function in subjects suffering with chronic, refractory axial low back pain with a neuropathic component, who have not had lumbar spine surgery and for whom surgery is not an option.

Detailed Description

A prospective, multi-center, randomized, controlled clinical study with an optional crossover component. The study is designed to evaluate the efficacy of BurstDR SCS in the treatment of chronic axial low back pain with a neuropathic component, compared to conventional medical management (CMM). Subjects will be followed in-clinic at 1,3, 6, 9, 12, 18 and 24 months and via phone call or optional clinic visit at 15- and 21-months. The primary endpoint will be assessed at the 6-month follow-up visit. Upon completion of the 6-month follow-up visit, subjects who are dissatisfied with therapy and receiving inadequate improvement with their treatment assignment will be allowed to cross-over to the other treatment arm, if desired. The study will enroll up to 270 patients at up to 30 sites. Subjects will be randomized in a 3:2 fashion to yield approximately 200 evaluable subjects for the primary endpoint analysis.

Registry
clinicaltrials.gov
Start Date
July 31, 2020
End Date
February 26, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient must be willing and able to provide written informed consent prior to any clinical investigation-related procedure.
  • Age ≥ 18 years
  • Patient has chronic (at least 6 months), refractory axial low back pain with a neuropathic component and is not a candidate for spine surgery
  • Patient has back pain for ≥ 6 months inadequately responsive to supervised conservative care
  • Patient has not had spine surgery for back or leg pain
  • Patient is a candidate for spinal cord stimulation
  • Low back pain ≥ 6 on Numerical Rating Scale
  • Oswestry Disability Index score of ≥ 30%
  • Willing and able to comply with the instructions for use, operate the study device, and comply with this Clinical Investigation Plan

Exclusion Criteria

  • Pathology seen on imaging tests obtained within the past 12 months that is clearly identified and is likely the cause of the CLBP, that can be addressed with surgery.
  • Primary complaint of leg pain, or leg pain is greater than back pain
  • Back pain is due to any of the following:
  • spinal instability defined as \> 2 mm translation on radiographic imaging
  • visceral causes (e.g., endometriosis or fibroids)
  • vascular causes (e.g., aortic aneurysm)
  • spinal infection (e.g., osteomyelitis)
  • inflammation or damage to the spinal cord (e.g. arachnoiditis or syringomyelia)
  • tumor or spinal metastases
  • Has widespread pain (e.g. fibromyalgia) or pain in other area(s), not intended to be treated in this study (e.g. neck pain, shoulder pain)

Outcomes

Primary Outcomes

The Difference in Responders Between Both Groups

Time Frame: 6 Months

Improvement in pain, defined as percentage of patients who report a ≥ 50% decrease on Numeric Rating Scale (NRS).

Secondary Outcomes

  • Measure of Composite Responder Rate(6 Months)
  • Numerical Rating Scale (NRS) Relative Change From Baseline to 6 Months(Baseline to 6 Months)
  • Oswestry Disability Index (ODI) Change From Baseline to 6 Months(Baseline to 6 Months)
  • Pain Catastrophizing Scale (PCS) Responder Rate(6 Months)
  • Patient Global Impression of Change (PGIC) Responder Rate(6 Months)
  • Patient-Reported Outcomes Measurement Information System (PROMIS-29) Pain Interference Relative Change From Baseline to 6 Months(Baseline to 6 Months)
  • Patient-Reported Outcomes Measurement Information System (PROMIS-29) Physical Function Relative Change From Baseline to 6 Months(Baseline to 6 Months)

Study Sites (30)

Loading locations...

Similar Trials